Overview

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis